Pulmonary Embolism Management Guidelines

Introduction to PE Management

The European Society of Cardiology recommends a comprehensive, risk-stratified approach to PE management, with direct oral anticoagulants (DOACs) now preferred over warfarin for most patients, and thrombolysis reserved strictly for high-risk PE with hemodynamic instability 1

The European Society of Cardiology guidelines categorize PE into three risk categories: high-risk, intermediate-risk, and low-risk, which determine treatment intensity 1
High-risk PE is characterized by hemodynamic instability with systolic hypotension or cardiogenic shock requiring vasopressors 1, 2
Intermediate-risk PE is characterized by hemodynamic stability but with evidence of right ventricular dysfunction on imaging or elevated cardiac biomarkers 2
Low-risk PE is characterized by hemodynamic stability without right ventricular dysfunction or myocardial injury 2

The European Society of Cardiology recommends immediate unfractionated heparin with weight-adjusted bolus and continuous infusion for high-risk PE without waiting for diagnostic confirmation 1, 2, 3
Systemic thrombolytic therapy is the Class I recommendation for all high-risk PE unless absolute contraindications exist 1, 2
Surgical pulmonary embolectomy is recommended when thrombolysis is contraindicated or has failed 1, 4

The European Society of Cardiology recommends DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) in preference to vitamin K antagonists (VKAs) for all eligible patients (Class I, Level A) 1, 5, 6
When VKAs are used, overlap with parenteral anticoagulation until INR reaches 2.5 for 2 consecutive days 1, 5, 6

The European Society of Cardiology does not recommend DOACs in patients with severe renal impairment, pregnancy, lactation, or antiphospholipid antibody syndrome (Class III, Level C) 1, 5

All patients with PE require therapeutic anticoagulation for at least 3 months 6
The European Society of Cardiology recommends discontinuing anticoagulation after 3 months for first PE secondary to major transient/reversible risk factor, and continuing indefinitely for recurrent VTE or antiphospholipid antibody syndrome 6

The European Society of Cardiology recommends LMWH as the preferred initial and long-term treatment for cancer patients 3
Therapeutic fixed doses of LMWH based on early pregnancy weight are recommended for hemodynamically stable pregnant women 6

The European Society of Cardiology encourages the formation of multidisciplinary rapid-response teams for severe PE cases (high-risk and selected intermediate-risk) 4